Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Binodenoson. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A known ✓ | P29274 | 13/20 | 0.98 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.98 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Binodenoson SCHEMBL10089218 | 1.00 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL13259764 | 1.00 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL8932230 | 1.00 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL8922719 | 1.00 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL724956 | 1.00 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL23898649 | 1.00 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL12877884 | 1.00 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL724955 | 1.00 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| Binodenoson SCHEMBL29379829 | 1.00 | ADORA2A (0.98) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL9346051 | 0.99 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130136693-A1 | Crystal Forms of 2--Adenosine | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC (US) | 2013-05-30 | — | — | US | claimed |
| US-20110189255-A1 | DRUG-ELUTING STENTS FOR ADENOSINE RECEPTOR MODULATION | PURDUE RESEARCH FOUNDATION | 2011-08-04 | — | — | US | claimed |
| US-20110044904-A1 | CRYSTAL FORMS OF 2--ADENOSINE | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2011-02-24 | — | — | US | claimed |
| EP-2257162-A2 | CRYSTAL FORMS OF 2-{2-Ý(CYCLOHEXYL)METHYLENE¨HYDRAZINO}ADENOSINE | King Pharmaceuticals Research and Development Inc. (US) | 2010-12-08 | — | — | EP | claimed |
| US-20100272711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | THOMAS JEFFERSON UNIVERSITY (US) | 2010-10-28 | — | — | US | claimed |
| WO-2009108829-A2 | CRYSTAL FORMS OF 2-{2-[(CYCLOHEXYL)METHYLENE]HYDRAZINO}ADENOSINE | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-09-03 | — | — | WO | claimed |
| WO-2009076580-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | THOMAS JEFFERSON UNIVERSITY (US) | 2009-06-18 | — | — | WO | claimed |
| US-20060205671-A1 | Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury | EMORY UNIVERSITY | 2006-09-14 | — | — | US | claimed |
| EP-1638579-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2006-03-29 | — | — | EP | claimed |
| EP-1014995-A4 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | ADERIS PHARMACEUTICALS INC (US) | 2005-02-16 | — | — | EP | claimed |
| WO-2005003150-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2005-01-13 | — | — | WO | claimed |
| US-6372723-B1 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS, INC. | 2002-04-16 | — | — | US | claimed |
| JP-2002505687-A | — | — | 2002-02-19 | — | — | JP | claimed |
| US-6339072-B2 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS INC. | 2002-01-15 | — | — | US | claimed |
| US-20010009907-A1 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS, INC. | 2001-07-26 | — | — | US | claimed |
| EP-1014995-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | Discovery Therapeutics, Inc. (US) | 2000-07-05 | — | — | EP | claimed |
| WO-1998057651-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | DISCOVERY THERAPEUTICS, INC. (US) | 1998-12-23 | — | — | WO | claimed |
| US-10953015-B2 | Use of adenosine receptor signaling to regulate P-gp function | CORNELL UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| US-5278150-A | Vasodilation | WHITBY RESEARCH, INC. (US) | 1994-01-11 | — | — | US | disclosed |
| EP-0567094-A2 | Hydrazoadenosines | Discovery Therapeutics, Inc. (US) | 1993-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130136693-A1 | Crystal Forms of 2--Adenosine | ADORA2A, NT5C2, ADORA3 | ADORA2A 1/4885ADORA1 4/4885ADORA2B 5/4885 |
| US-20110044904-A1 | CRYSTAL FORMS OF 2--ADENOSINE | ADORA2A, NT5C2, ADORA3 | ADORA2A 1/4885ADORA1 4/4885ADORA2B 5/4885 |
| US-20100272711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885ADORA1 2/4885ADORA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.